Table 3.
Baseline, Placebo and Post-Placebo PSAS Total Scores (Mean ± SD) for 103 Patients in Analysis 2
Baseline | Placebo |
Post-placebo day
|
|||||||
---|---|---|---|---|---|---|---|---|---|
3 | 7 | 14 | 21 | 28 | 35 | 42 | |||
Mean | 23.54 | 38.29a* | 32.42a* | 30.73a* | 31.22a* | 32.31b* | 27.96c* | 29.89b* | 27.71d |
SD | 12.10 | 15.82 | 18.02 | 18.03 | 19.36 | 19.58 | 16.97 | 17.59 | 17.91 |
Mean difference | 14.81 | 8.94 | 7.25 | 7.74 | 8.82 | 4.47 | 6.41 | 4.23 | |
95% CI | 12.67 11.79 | 12.67 5.21 | 10.61 3.88 | 11.17 4.31 | 12.28 5.37 | 7.84 1.11 | 9.76 3.06 | 7.66 0.81 | |
Percent of patients returned to baseline plus 1SD | 53 | 53 | 56 | 59 | 63 | 66 | 66 |
Paired t tests compared with baseline
p ≤.0001,
p ≤.001,
p ≤.01,
p ≤.05.
Repeated measure ANOVA, (Greenhouse-Geisser), df and ε [6.30, 642.4] and 0.79, respectively; F = 12.41; p < .0001,
Bonferroni t p = .05, compared with baseline only.